A question raised in the packed Sept. 16 conference session spoke to everyone’s fears about overzealous investigators and how they might use FDA’s new authority to deem product adulterated whenever they believe someone is obstructing their inspection.
Recent warning letters suggest that only extreme cases will trigger FDA’s use of this powerful authority granted by section 707 of last year’s FDA Safety and Innovation Act.
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?